For individuals battling treatment-resistant depression, SPRAVATO® (esketamine) offers a promising path to relief. Unlike traditional antidepressants, which primarily target neurotransmitters such as serotonin, dopamine, and norepinephrine, SPRAVATO® works by affecting NMDA (N-methyl-D-aspartate) receptors in the brain. This unique mechanism of action helps to regulate glutamate, an important neurotransmitter involved in...
